Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim
Can we “Netflix” the Broken Antibiotics Market?
To access the recording please click here.
Building on the learnings from the NICE and NHS England pilot with a subscription-style approach to purchasing and evaluating antibiotics.
Antibiotics are the foundation of medicine, but growing antibiotic resistance and a lack of new antibiotics being developed pose a significant threat to society.
Antibiotics are the foundation of medicine, but growing antibiotic resistance poses a significant threat to society. The antibiotics market is broken because companies do not see a return of investment in antibiotics. As a result, there is underinvestment in antibiotic development; no new classes of antibiotics have been discovered since the 1980s and many companies have moved out of the space entirely.
NICE and NHS England took an important first step towards fixing the broken antibiotics market by piloting a Netflix-style model for the evaluation and purchase of antimicrobials. The model, a form of pull-incentive for antibiotics, could increase returns for companies developing antibiotics and stimulate investment in new antibiotics if adopted by enough other countries. The learnings from this pilot are manifold and will shape the future of antimicrobial purchasing and assessment in England and beyond for years to come.
OVERVIEW
In this webinar, OHE’s Lotte Steuten was joined by Nick Crabb (NICE), David Glover (NHS England) and Jason Gordon (HEOR Consulting) to discuss their experience with evaluation and purchasing of antimicrobials and how to build on the learnings from the NICE NHS England AMR pilot:
- How much should the UK pay for new antibiotics?
- How should we value new antibiotics?
- What does the future look like for antibiotic purchasing and evaluation across the world?
SPEAKERS
Dr Nick Crabb, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE)
Nick had a 20-year career in analytical science, process technology and general management in the chemical, pharmaceutical and contract laboratory industries prior to joining NICE in 2010 to establish and manage the Diagnostics Assessment Programme. Nick currently oversees NICE’s Science Policy and Research programme. Nick has broad scientific and policy interests relating to the evaluation of technologies and interventions to support the development of clinical, public health and social care guidance. His experience includes consideration of HTA issues arising from the availability of novel new products such as cell and gene therapies and work on methods issues relating to the evaluation of antimicrobials. Nick is also the NICE lead on a collaborative project with NHS England to develop and test innovative models for the evaluation and purchase of antimicrobials.
David Glover, Deputy Head of the Medicines Analysis Team at NHS England and Improvement
David Glover became Deputy Head of the Medicines Analysis Team at NHS England and Improvement, in January 2019. Prior to joining the NHS, David worked in central government for over 20 years, including 15 years as an economic adviser to the Department of Health and Social Care and the Office for Life Sciences, having also spent six years as a patent examiner at the UK Intellectual Property Office. He was part of the NICE-NHS England AMR Pilot project team.
Jason Gordon, Chief Commercial Officer and Co-Founder , HEOR
For over 15 years, Jason has shaped health economics and market access strategies and evidence for the world’s leading pharmaceutical and biotechnology companies. Following careers in academia, consultancy, industry and government, Jason has developed his passion for helping companies define the value of new and innovative treatments and form partnerships that optimise patient access and product commercialisation. Jason received his Bachelor of Economics with honours and postgraduate economics training from the University of Adelaide, and a Doctorate in Health Economics from the University of Birmingham.
